Chinese Journal of Blood Purification

Chinese Journal of Blood Purification ›› 2022, Vol. 21 ›› Issue (05): 365-368.doi: 10.3969/j.issn.1671-4091.2022.05.014

Previous Articles     Next Articles

Application of anti-Xa factor activity assay in low molecular weight heparin anticoagulation in hemodialysis patients 

WANG Zhen-xing1, XU Leng-nan1, FU Pei-jie1, DANG Xin1, MAO Yong-hui   

  1. 1Department of Nephrology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric medicine, Chinese Academy of Medical Sciences, Beijing 100005, China
  • Received:2021-11-08 Revised:2021-12-05 Online:2022-05-12 Published:2022-05-12
  • Supported by:
    Fees for basic scientific research in the central university of Peking Union Medical College

PDF

777

Abstract: Low molecular weight heparin (LMWH) is one of the commonly used anticoagulants. Its anticoagulation effect and bleeding risk are often monitored by the anti-Xa factor activity. Appropriate anti-Xa factor activity range is also recommended in clinical guidelines. As for hemodialysis patients using LMWH, there is no consensus about the target range of anti-Xa factor activity. This review mainly discusses the value of anti-Xa factor activity assay in LMWH anticoagulation for hemodialysis and the recent progresses in its specific monitoring strategies.

Key words: Hemodialysis, Low molecular weight heparin, Anti-Xa activity

CLC Number: